DESTINATION 2
prostate cancer; tests no drug
DESTINATION 2 asks whether lowering radiotherapy dose to benign-appearing prostate while preserving dose to MRI-visible tumours can reduce urinary toxicity without compromising cancer control in localized prostate cancer. Commentary comes from X threads, podcasts and a YouTube video. The discussion turns on whether the two-fraction dose is adequate, how to interpret contested target-specific margin reduction, and what conditions would make MR-guided adaptation scalable.
- NCT06638541 ↗
- v1.0.0 · edition 1
- updated Oct 31, 2026
- Standard
12 findings, and what sits behind each
01. Support for de-escalation does not settle whether the two-fraction dose is sufficient
7 statements · 7 passages · 4 sources · 5 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: The comparison, Secondary endpoints, Safety and tolerability.
02. The margin controversy is target-specific and includes biological as well as geometric uncertainty
7 statements · 5 passages · 3 sources · 3 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: The comparison, Safety and tolerability, Secondary endpoints.
03. Whether focal escalation adds benefit depends on the whole-gland dose, fractionation and evidence standard
8 statements · 8 passages · 1 sources · 6 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: The comparison, Safety and tolerability.
04. Selection includes surveillance and the option of a longer course, not just choosing a boost
7 statements · 8 passages · 3 sources · 4 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Population and setting, Safety and tolerability, Secondary endpoints.
05. MRI-enabled targeting is attractive, but lesion definition and response adaptation remain uncertain
10 statements · 9 passages · 3 sources · 4 named voices
Counterview: recorded · Limitations recorded: 2.
Draws on: Population and setting.
06. Urethral protection ranges from selective contouring to routine sparing
12 statements · 13 passages · 1 sources · 6 named voices
Counterview: recorded · Limitations recorded: 2.
Draws on: Safety and tolerability, The comparison.
07. Rectal safety concerns are expressed through concrete planning safeguards and reluctance to escalate further
6 statements · 6 passages · 1 sources · 3 named voices
Counterview: recorded · Limitations recorded: 2.
Draws on: Safety and tolerability.
08. Spacer use remains a conditional benefit–burden discussion rather than a settled requirement
10 statements · 10 passages · 3 sources · 8 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, The comparison.
09. The early-toxicity endpoint is defended as developmental evidence, not a substitute for mature outcomes
9 statements · 9 passages · 2 sources · 0 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Primary endpoint: Acute GU toxicity, Secondary endpoints.
10. Federated recruitment is welcomed, but operational success and statistical interpretation remain separate
7 statements · 4 passages · 2 sources · 1 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Design and conduct, Population and setting.
11. Scalability depends on staffing, contour consistency and demonstrating the value of MR-guided adaptation
10 statements · 9 passages · 3 sources · 3 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Design and conduct, Population and setting.
12. Research incentives and reimbursement can obstruct otherwise attractive treatment-shortening research
11 statements · 10 passages · 2 sources · 3 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 12
Support for de-escalation does not settle whether the two-fraction dose is sufficient
- statements
- 7
- passages
- 7
- sources
- 4
- named voices
- 5
What the statements areViews 3Questions and uncertainty 2Clinical experience 0Comparisons 1Restated results and context 1How passages are usedSupporting a statement 8Giving context 1Recorded with the finding- Counterview: recorded
- Limitations: 2
- Feeds the Medical Affairs question
- 2 posts and articles
- 1 podcast or video
- 1 publication
Draws on: The comparison, Secondary endpoints, Safety and tolerability.
In the full report: the interpretation in full, all 7 statements cited to source and date, and the 4 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full DESTINATION 2 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
What evidence of preserved cancer control, meaningful patient-reported benefit and reproducible delivery would justify moving this experimental approach beyond its current research setting?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 20HCP commentary sources screened
- 17sources cited by verified HCP statements
- 27named in screened sources
- 25voices cited in the report
- 20cited voices matched to verified clinician profiles
- 172verified statements, each linked to its source
- 56of them from speakers with a confirmed clinical role
- 12findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Standard) is set by the 172 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians. A confirmed clinical role is one verified by the NPI registry or by the person's own institution's staff page; a role a source only states is not counted.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 172 | Paid |
| Trial aspects mapped | 10 | Free |
| Sources with links | 17 | Counts free |
| Speaker attribution for cited voices | 25 | Paid |
Trial aspects
10 discussed · 0 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Acute GU toxicity | 3 | 1 |
| Secondary endpoints | 15 | 9 |
| Population and setting | 8 | 3 |
| The comparison | 39 | 11 |
| Safety and tolerability | 26 | 8 |
| Design and conduct | 19 | 6 |
| Imaging validation, contour consistency and response-guided adaptation | 26 | 5 |
| Urethral and rectal protection, spacer use and planning exceptions | 34 | 3 |
| Platform access, workforce, research funding and reimbursement | 21 | 2 |
| Patient priorities, routine-care alternatives and the boundary of research | 34 | 8 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 16 | 12 | |
| Podcasts | 3 | 3 | |
| YouTube | 1 | 1 | |
| Primary sources, cited for context, not screened | |||
| Publications | not screened | 1 | |
max 4 / quarter
- Screened window
- Oct 11, 2024 → Oct 28, 2026
- Cited window
- Oct 11, 2024 → Oct 28, 2026
- Retrieved
- Oct 31, 2026
The trial
from ClinicalTrials.gov- Title
- Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions - a Randomised Trial
- Registry
- NCT06638541
- Study IDs
- CCR5984 · 338368 (IRAS)
- Sponsor
- Royal Marsden NHS Foundation Trust
- Collaborators
- Elekta Limited, MRL Consortium
- Design
- Not applicable · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 54 estimated
- Registered
- 2024-10-15
- Start
- 2025-01-20 actual
- Primary completion
- 2027-01-01 estimated
- Primary endpoint
- Acute GU toxicity
- Interventions
- 1 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on imaging to avoid missing cancer when selecting tissue for prostate radiotherapy.
- Not yet captured in this edition: a remark on trial origins, hypothesis-testing role, protocol availability, ongoing recruitment and feedback shaping experimental design.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 57 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The report covers only the sources reviewed for this edition, not all clinicians or all public discussion. Some potentially relevant passages were not fully assessed, and trial-name searches may miss unnamed references or wording variants.
- No DESTINATION 2 clinical outcome results are provided. The protocol publication describes planned methods and hypotheses, while interview and social-media recruitment statements describe progress at their own timepoints.
- Several podcast passages cannot be assigned to a named speaker. They are not attributed to a speaker simply because the same episode includes clearly attributed statements from the speaker.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Trial involvement and presentation roles are described as the sources describe them; such involvement does not make a view independent external validation.
- External-study comparisons, radiobiological calculations, economic arguments and personal experience remain attributed interpretations. They do not independently establish DESTINATION 2 efficacy, toxicity, procedural safety or cost-effectiveness.
- Views about other fractionations, brachytherapy and planning safeguards are included where they inform the localized-prostate treatment decision. They are not presented as DESTINATION 2 protocol requirements.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. DESTINATION 2 (NCT06638541): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/destination-2-nct06638541
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "DESTINATION 2" (NCT06638541), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "destination-2-06638541". If you cannot make requests, read https://www.erudio.com/reports/destination-2-nct06638541.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06638541", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06638541 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/destination-2-nct06638541.json
curl https://www.erudio.com/reports/destination-2-nct06638541.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "destination-2-06638541" })release 205028e2efca7be1eca08bf9a6717de3e4186644a7f5a48ee5d7e0a492cb2ad0